International Liver Congress
International Liver Congress
April 14, 2018
1 min read
Save

8-weeks of Zepatier may effectively treat HCV genotype 4

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PARIS — In patients with hepatitis C virus genotype 4, 8 weeks of Zepatier showed effective treatment of the virus, according to a presentation at the International Liver Congress 2018.

“This is an ongoing study investigating a novel 8-week treatment regimen of elbasvir/grazoprevir in participants with genotype 4 infection,” Tarik Asselah, MD, University Paris Diderot, said in his presentation. “We have high rates of SVR among treatment-naive participants with mild to moderate fibrosis who have completed follow up.”

The study Asselah presented included patients with HCV genotype 4. The researchers randomly assigned treatment-naive participants with mild to moderate fibrosis to receive Zepatier (elbasvir/grazoprevir, Merck) for 8 weeks (n = 53) or 12 weeks (n = 64).

In the 8-week group, two virologic relapses occurred and, overall, the regimen showed an excellent safety profile with no serious adverse events, discontinuations or elevation of alanine aminotransferase or aspartate aminotransferase levels, Asselah said.

“Final results from 8-week arm plus outcomes in participants treated for 12 weeks will provide further information regarding the effective use of this regimen in genotype 4 infection,” he concluded. – by Katrina Altersitz

For more information:

Asselah T, et al. GS-006. Presented at: International Liver Congress; Apr. 11-15, 2018; Paris, France.

Disclosure: Asselah reports he is speaker and investigator for AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck and Roche.